JP2004093563A - 前立腺特異抗原の免疫検定法 - Google Patents
前立腺特異抗原の免疫検定法 Download PDFInfo
- Publication number
- JP2004093563A JP2004093563A JP2003286450A JP2003286450A JP2004093563A JP 2004093563 A JP2004093563 A JP 2004093563A JP 2003286450 A JP2003286450 A JP 2003286450A JP 2003286450 A JP2003286450 A JP 2003286450A JP 2004093563 A JP2004093563 A JP 2004093563A
- Authority
- JP
- Japan
- Prior art keywords
- psa
- antibody
- analyte
- complex
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
【解決手段】前立腺特異抗原(PSA)の新たな免疫検定法。また、PSA用の免疫検定法においてキャリブレータまたは対照として使用できるPSAとα−抗キモトリプシン(ACT)の複合体に似た複合体、および、PSAに対するポリクロナール抗体を、PSAがACTに結合することでマスクされるエピトープと結合するもの、およびこのようなエピトープと結合しないものに分別する方法。
【選択図】なし
Description
本発明は1つの態様として、サンプル中のPSAを検出して定量するための新しいMOLY検定法およびMONO検定法を提示する。これらの方法では遊離PSAとは結合するがPSAとACTの複合体(「PSA−ACT複合体」)とは結合しないHEPSA抗体でサンプルを処理する。検定法にHEPSA抗体を加えることで、これらの検定法におけるバイアスが減るかもしくは排除される。これらの検定法を実施するためのキットも提示する。
ここでいう「抗体」とは、ポリクロナール抗体およびモノクロナール抗体、免疫グロブリン全長ならびに免疫グロブリンの抗原結合フラグメントを含む。これらのフラグメントの例としては、Fab、F(ab’2)およびFvがある。このようなフラグメントは、当該技術分野で既知の方法により作製できる。
I.新しいPSA免疫検定法
図1では、従来のPSA MOLY検定法(パートA)および本発明のPSA MOLY検定法(パートB)を比較して、HEPSA抗体が遊離PSAおよびPSA−ACT複合体に特異な検定法をいかに改良するかを示している。
II.被検体に対するポリクロナール抗体の分別方法
本発明は、被検体に対するポリクロナール抗体を分別してそれぞれHE抗体および非HE抗体を含有する分画をもたらす方法も提示する。被検体に対するポリクロナール抗体は、当該技術分野で既知の方法を使って産生できる。たとえば、ウサギ、ラット、ヤギ、マウス、等々の宿主動物に被検体またはそのフラグメントを単独であるいは必要に応じて適当な担体に接合させて注入し、抗体反応を引き起こして抗体を生み出すことができる。
ACTを、臭化シアン活性化セファロース−4B(Pharmacia LKB Biotechnology、スウェーデンから市販)などの固相に抱合させる。精製したPSAをACTと反応させて、隠れるエピトープ(HE)をマスクするPSA−ACT複合体が生成する。この複合体を化学的架橋によりさらに安定させることもできる。PSAに対するポリクロナール抗体をPSA−ACT−固相とインキュベートすると、HEPSA抗体は未結合である。隠れていないエピトープに特異な非HEPSA抗体、たとえばnHE1およびnHE2は結合し、低pHなどの標準的方法で溶出できる。こうして、ポリクロナール抗PSA抗体がHEPSA抗体および非HEPSA抗体に分離される。
隠れていないエピトープ1(nHE1)に向けた非HEPSA抗体(αnHE1)を、臭化シアン活性化セファロース−4Bなどの固相に抱合させる。精製したPSAをαnHE1と反応させて、PSA−αnHE1複合体を生成する。HEPSA抗体(αHE)をPSA−αnHE1と反応させて、隠れているエピトープ(HE)をマスクする複合体を精製する。この複合体を化学的架橋によりさらに安定させることもできる。PSAに対するポリクロナール抗体を固相−αnHE1−PSA−αHEとインキュベートすると、HEおよびnHE1に対する抗体は固相に結合しない。nHE1以外の隠れないエピトープに対する非HEPSA抗体は固相に結合し、低pHなど標準的な方法で溶出できる。固相に結合しない抗体は、方法AまたはBによってさらに分離することができる。こうして、ポリクロナール抗PSA抗体はHEPSA抗体、nHE1に対する抗体、およびnHE1以外のnHEに分離される。特定のαHEがPSA上のHEすべてをマスクしない場合には、他のHE部位に向けた追加のHE抗体を同時に、あるいは好ましくは逐次分画カラムで使用することができる点に注目されたい。
III.PSA検定のキャリブレーターおよび対照として有用な被検体−HE抗体の複合体
本発明では、被検体の検定におけるキャリブレーターおよび対照として役立つ被検体−HE抗体の複合体も提示する。この複合体は、被検体に過剰なHE抗体を加えることで生成できる。HE抗体は、被検体の2倍から100倍多いことが好ましく、10倍多いことがより望ましい。あるいは、被検体をHE区隊に架橋することができる。前述の被検体と結合分子の架橋方法が、被検体とHE抗体の架橋にも同じく適用できる。複合体は、リン酸緩衝食塩水、トリス−HCl、またはHEPESなどの不活性緩衝液中に保存するのが好ましい。貯蔵温度は2〜25℃が望ましい。pHは5〜9が望ましい。被検体の検定でキャリブレーターまたは対照の役もなす被検体とその結合分子の架橋複合体も、同じようにして生成できる。
以下の実験は、IMx(登録商標)PSA Assay用試薬を使用し、IMx(登録商標)PSA Assay添付書の手順に従ってIMx(登録商標)機器(本出願人)で実施したが、本発明では遊離PSAとは結合するがPSA−ACT複合体とは結合しないMAB 9B10または5A10(前述)0〜20μg/mLを追加含有する検定用希釈剤を使用した点のみ異なる。IMx(登録商標)PSA Assay試薬としては次のものがある。(1)遊離PSAおよび複合体化PSA(すなわちACTと複合体を形成したPSA)の双方と結合し捕捉する捕捉抗体MAB H50で被覆された微粒子(「抗PSA被覆微粒子」)、および(2)検出用にアルカリホスファターゼで標識されたPSAに対するヤギポリクロナール抗体(プローブ抗体として働く)(「ヤギポリクロナール抗PSA:アルカリホスファターゼ抱合体」または「プローブポリクロナール抗体」)。
b.Abbott IMx(登録商標)PSA Assayおよび9B10の入った検定希釈剤(すなわち検定希釈剤に10μg/mLの9B10を添加)
c.Abbott IMx(登録商標)PSA AssayおよびMAB H50プローブ抗体ならびにMAB H117捕捉抗体(すなわちH117被覆微粒子および標識H50を使用)
前述のようにして検定を行った。表4に、遊離PSAサンプルおよびACTを添加したPSAサンプルで得られたPSAの量を示す。PSA対照に比べて、ACTを含有するサンプルで検出されたPSAの量が少ない場合、バイアスが生じているのを示す。
HEPSA抗体をPSAと混和するとPSA−HEPSA抗体複合体が形成され、そこでは隠れるエピトープはPSA−ACT複合体と同様にブロックされる。この物質を、PSA検定でキャリブレーターまたは対照として利用することができる。
本実施例では、前記図2のパートBで示した分別方法の実行について説明する。方法を説明するのにMAB 5A10を使用するが、これの代わりにどのようなHEPSA抗体でも、たとえばMAB 9B10などを使用することができる。
Claims (4)
- αHE抗体に架橋した生体サンプルからの被検体を含んで成る複合体で、該被検体は遊離被検体としても、あるいは結合分子と結合して被検体−結合分子複合体を形成した形でも存在でき、該被検体は少なくとも1つの隠れたエピトープと隠れていないエピトープを有し、αHE抗体は遊離被検体に結合できるが被検体−結合分子複合体とは結合できない被検体に対する抗体である複合体。
- 被検体がPSAおよび結合分子がACTである、請求項1に記載の複合体。
- 結合分子に架橋する生体サンプルからの被検体で、該被検体は生体サンプル中に遊離被検体としても、あるいは生体サンプルに内在性の結合分子に結合して被検体−結合分子複合体を形成した形でも存在することができ、且つ、少なくとも1つの隠れたエピトープと隠れていないエピトープを有する被検体。
- 請求項2に記載の複合体の被検体の検定におけるキャリブレータまたは対照としての使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/174,964 US5599677A (en) | 1993-12-29 | 1993-12-29 | Immunoassays for prostate specific antigen |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51816495A Division JP3486413B2 (ja) | 1993-12-29 | 1994-12-22 | 前立腺特異抗原の免疫検定法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004093563A true JP2004093563A (ja) | 2004-03-25 |
JP3833637B2 JP3833637B2 (ja) | 2006-10-18 |
Family
ID=22638254
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51816495A Expired - Lifetime JP3486413B2 (ja) | 1993-12-29 | 1994-12-22 | 前立腺特異抗原の免疫検定法 |
JP2003286450A Expired - Lifetime JP3833637B2 (ja) | 1993-12-29 | 2003-08-05 | 前立腺特異抗原の免疫検定法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51816495A Expired - Lifetime JP3486413B2 (ja) | 1993-12-29 | 1994-12-22 | 前立腺特異抗原の免疫検定法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5599677A (ja) |
EP (1) | EP0741868B1 (ja) |
JP (2) | JP3486413B2 (ja) |
AT (1) | ATE290212T1 (ja) |
AU (1) | AU1518795A (ja) |
DE (1) | DE69434286T2 (ja) |
ES (1) | ES2238678T3 (ja) |
WO (1) | WO1995018381A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016194437A (ja) * | 2015-03-31 | 2016-11-17 | 株式会社Lsiメディエンス | 前立腺特異抗原の測定方法及び測定キット |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9002480D0 (sv) * | 1990-07-23 | 1990-07-23 | Hans Lilja | Assay of free and complexed prostate-specific antigen |
US5723302A (en) * | 1993-05-14 | 1998-03-03 | Nordion International Inc. | Detection of prostate-specific antigen in breast tumors |
US5654161A (en) * | 1995-05-12 | 1997-08-05 | Chiron Diagnostics Corporation | Method for diagnosing prostate cancer |
EP0789032A2 (en) * | 1996-02-01 | 1997-08-13 | Bayer Corporation | Method for preparing a monoclonal antibody that provides an equimolar response to free and complexed analyte in a monoclonal/polyclonal sandwich immunoassay |
US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6136311A (en) * | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
EP0912890A4 (en) * | 1996-07-03 | 2002-01-02 | Millennium Pharm Inc | CANCER DETECTION BY DETERMINING ANTIGENS WEARING THE TRIANTENNARE OLIGOSACCHARID |
DE19641560A1 (de) * | 1996-10-09 | 1998-04-16 | Boehringer Mannheim Gmbh | Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease |
US5840501A (en) * | 1996-10-25 | 1998-11-24 | Bayer Corporation | Determination of cPSA |
IL121659A (en) * | 1996-10-25 | 2000-07-16 | Bayer Ag | Method for determining CPSA in a blood sample |
US5856182A (en) * | 1996-11-18 | 1999-01-05 | Beckman Coulter, Inc. | Monoclonal antibodies specific for the PSA-ACT complex |
US6548260B1 (en) * | 1997-01-21 | 2003-04-15 | Bayer Corporation | Detection of PSA-α2-macroglobulin complex in a biological fluid |
US7288636B2 (en) * | 1997-04-30 | 2007-10-30 | Hybritech Incorporated | Forms of prostate specific antigens and methods for their detection |
EP0983509B1 (en) * | 1997-05-14 | 2005-08-17 | Biosite Diagnostics Inc. | Rapid evaluation of the ratio of biological molecules |
US6780598B1 (en) * | 1997-06-13 | 2004-08-24 | William J. Kokolus | Method of identifying and locating immunobiologically-active linear peptides |
CA2243033A1 (en) * | 1997-07-31 | 1999-01-31 | Bayer Corporation | Determination of psa-act |
US6194152B1 (en) | 1997-08-20 | 2001-02-27 | Dendreon Corporation | Prostate tumor polynucleotide compositions and methods of detection thereof |
US6649420B1 (en) * | 1997-08-26 | 2003-11-18 | Thomas L. Cantor | Methods and devices for detecting no-complexed prostate specific I antigen |
US5994085A (en) * | 1997-08-26 | 1999-11-30 | Cantor; Thomas L. | Methods and devices for detecting non-complexed prostate specific antigen |
WO1999012553A1 (en) | 1997-09-08 | 1999-03-18 | Idec Pharmaceuticals Corporation | Methods for producing human antibodies in scid mice using dendritic cells |
US6300088B1 (en) | 1997-11-24 | 2001-10-09 | Duke University | Method of detecting prostate specific antigen |
US6352834B1 (en) * | 1998-07-17 | 2002-03-05 | University Of Iowa Research Foundation | Prostate cancer assays and related methods |
CA2360073C (en) | 1999-01-28 | 2011-01-18 | Gen-Probe Incorporated | Probes and primers for detecting prostate specific antigen (psa) in a biological sample |
EP1194768A4 (en) | 1999-04-20 | 2008-03-26 | Target Discovery Inc | FINGERPRINTING METHOD FOR POLYPEPTIDES, CREATING METABOLIC PROFILES, AND BIOINFORMATIVE DATABASE |
DE19957065B4 (de) * | 1999-11-26 | 2005-01-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Screening-Verfahren für Arzneistoffe |
FR2810114B1 (fr) * | 2000-06-13 | 2002-08-23 | Bio Merieux | Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate |
CA2415923C (en) | 2000-07-12 | 2011-10-25 | Agensys, Inc. | Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
ATE282205T1 (de) | 2000-07-24 | 2004-11-15 | Health Research Inc | Verfahren zur detektion von prostata-spezifischem membran-antigen in serum |
US6379550B1 (en) | 2000-07-24 | 2002-04-30 | Health Research, Inc. | Method for detecting PSA and its molecular forms using thiophilic gel |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US6764825B1 (en) * | 2000-10-13 | 2004-07-20 | Tang J. Wang | Methods and device for detecting prostate specific antigen (PSA) |
US6727104B2 (en) | 2001-02-05 | 2004-04-27 | The Board Of Regents Of The University Of Nebraska | Microcolumn chromatographic immunoassays |
US6500671B2 (en) | 2001-02-05 | 2002-12-31 | The Board Of Regents Of The University Of Nebraska | Loading microcolums for the separation of analytes from a sample in the millisecond time scale |
US6720193B2 (en) * | 2001-02-05 | 2004-04-13 | Board Of Regents Of The University Of Nebraska | Analysis of free analyte fractions by rapid affinity chromatography |
CA2442993C (en) * | 2001-04-10 | 2011-10-11 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
US7811575B2 (en) * | 2001-04-10 | 2010-10-12 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer |
WO2002096460A1 (en) * | 2001-05-30 | 2002-12-05 | Cornell Research Foundation, Inc. | Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer |
JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
US7666414B2 (en) * | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
WO2003024388A2 (en) * | 2001-09-20 | 2003-03-27 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for psma |
US7842498B2 (en) | 2001-11-08 | 2010-11-30 | Bio-Rad Laboratories, Inc. | Hydrophobic surface chip |
US20030165954A1 (en) | 2002-01-09 | 2003-09-04 | Third Wave Technologies, Inc. | Cancer profiles |
US7138230B2 (en) | 2002-12-06 | 2006-11-21 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
US20040018577A1 (en) * | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
US20040136998A1 (en) * | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
ES2424269T3 (es) * | 2002-11-01 | 2013-09-30 | Iris International, Inc. | Inmuno-PCR sándwich por desplazamiento |
ATE408712T1 (de) * | 2003-01-10 | 2008-10-15 | Millennium Pharm Inc | Verfahren zur bestimmung des wiederauftretens von prostata krebs |
US20040203079A1 (en) * | 2003-04-09 | 2004-10-14 | Research Foundation Of The State University Of New York | Methods and kits for detecting cerebrospinal fluid in a sample |
US20070003992A1 (en) * | 2003-04-09 | 2007-01-04 | Pentyala Srinivas N | Methods and kits for detecting cerebrospinal fluid in a sample |
US8003765B2 (en) * | 2003-04-09 | 2011-08-23 | Stony Brook Anaesthesiology, University Faculty Practice Corporation | Methods, antibodies and kits for detecting cerebrospinal fluid in a sample |
EP2003196A3 (en) * | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
US20050202020A1 (en) * | 2004-01-09 | 2005-09-15 | Jeffrey Ross | Diagnosing and treating cancer |
WO2005074633A2 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
WO2005094882A1 (en) * | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US20050266503A1 (en) * | 2004-05-24 | 2005-12-01 | Esoterix, Inc. | Simultaneous assay of target and target-drug binding |
US20060135455A1 (en) | 2004-06-01 | 2006-06-22 | Reza Sheikhnejad | Methods and compositions for the inhibition of gene expression |
WO2005118872A2 (en) * | 2004-06-01 | 2005-12-15 | The Regents Of The University Of Michigan | Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases |
US7858323B2 (en) | 2004-06-09 | 2010-12-28 | The Regents Of The University Of Michigan | Phage microarray profiling of the humoral response to disease |
CN101137758B (zh) | 2004-11-03 | 2012-10-10 | 意力速分子诊断股份有限公司 | 均相分析物检测 |
CN103091485A (zh) * | 2004-11-03 | 2013-05-08 | 艾瑞斯国际有限公司 | 用于亲和分离的微泡 |
US7439024B2 (en) * | 2005-06-01 | 2008-10-21 | The United States Of America As Represented By The Department Of Veterans Affairs | Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases |
WO2006135886A2 (en) * | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
CA2612021A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US8652467B2 (en) * | 2005-10-14 | 2014-02-18 | The Regents Of The University Of Michigan | Dek protein compositions and methods of using the same |
US7794951B2 (en) * | 2005-10-18 | 2010-09-14 | University Of Massachusetts Medical School | SREBP2gc transcription factors and uses thereof |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
PL2500360T3 (pl) | 2005-10-31 | 2016-01-29 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworu |
JP5129149B2 (ja) * | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を処置および診断するための組成物および方法 |
EP1998785A4 (en) * | 2006-02-21 | 2009-06-17 | Univ Michigan | CANCER TREATMENT USING A HEDGEHOG SIGNALING PATH |
ATE497023T1 (de) | 2006-06-12 | 2011-02-15 | Harvard College | Nanosensoren und entsprechende technologien |
US20080100279A1 (en) * | 2006-06-15 | 2008-05-01 | University Of South Florida | Nano-Based Device for Detection of Disease Biomarkers and Other Target Molecules |
US8349604B2 (en) * | 2006-06-15 | 2013-01-08 | University Of South Florida | Nano-based device for detection of disease biomarkers and other target molecules |
WO2008045952A2 (en) * | 2006-10-10 | 2008-04-17 | The Regents Of The University Of Michigan | Photoreceptor precursor cells |
US20080125582A1 (en) * | 2006-10-13 | 2008-05-29 | Bio-Rad Laboratories, Inc. | Methods and compositions for stabilizing prostate specific antigen |
WO2008127314A1 (en) | 2006-11-22 | 2008-10-23 | President And Fellows Of Harvard College | High-sensitivity nanoscale wire sensors |
EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
ES2687620T3 (es) | 2007-05-04 | 2018-10-26 | Opko Diagnostics, Llc | Dispositivo y método para análisis en sistemas microfluídicos |
EP2153232A1 (en) | 2007-05-18 | 2010-02-17 | Duke University | Serum biomarkers for the early detection of lung cancer |
US20090324596A1 (en) | 2008-06-30 | 2009-12-31 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
US10745701B2 (en) | 2007-06-28 | 2020-08-18 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
EP3424529A1 (en) | 2007-07-02 | 2019-01-09 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
EP2183592A4 (en) * | 2007-08-08 | 2011-03-16 | Renovar Inc | SYSTEMS AND METHOD FOR CHARACTERIZING LUPUS ERYTHEMATODES |
EP2201134B1 (en) | 2007-09-19 | 2018-11-21 | The Research Foundation of State University of New York | Gene expression signatures in enriched tumor cell samples |
WO2009091556A2 (en) * | 2008-01-17 | 2009-07-23 | The General Hospital Corporation | Diagnostic methods and kits using fibroblast growth factor-23 |
US20090246781A1 (en) * | 2008-02-21 | 2009-10-01 | Robert Klem | Method for early determination of recurrence after therapy for prostate cancer |
US20110092452A1 (en) * | 2008-03-05 | 2011-04-21 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
JP5792621B2 (ja) | 2008-09-26 | 2015-10-14 | オンコメッド ファーマシューティカルズ インコーポレイテッド | frizzled結合剤およびその使用 |
PL2356462T3 (pl) | 2008-11-11 | 2017-07-31 | The Regents Of The University Of Michigan | Kompozycje anty-CXCR1 oraz sposoby |
US8362318B2 (en) * | 2008-12-18 | 2013-01-29 | Board Of Trustees Of Michigan State University | Enzyme directed oil biosynthesis in microalgae |
US20100173791A1 (en) | 2009-01-05 | 2010-07-08 | Bio-Rad Laboratories, Inc. | Process design using mass spectrometry |
EP2391451B1 (en) | 2009-02-02 | 2018-09-12 | Opko Diagnostics, LLC | Structures for controlling light interaction with microfluidic devices |
US8481698B2 (en) * | 2009-03-19 | 2013-07-09 | The President And Fellows Of Harvard College | Parallel proximity ligation event analysis |
EP2411410B1 (en) | 2009-03-27 | 2015-07-08 | Gojo Industries, Inc. | Compositions and methods for screening and using compounds antagonizing spore-surface interactions |
US20100272824A1 (en) * | 2009-04-16 | 2010-10-28 | The Texas A&M University System | Compositions and methods for preventing and monitoring disease |
WO2011017605A2 (en) * | 2009-08-07 | 2011-02-10 | Affinimark Technologies, Inc. | Device and methods for the immunological identification of cerebrospinal fluid |
WO2011025540A1 (en) | 2009-08-28 | 2011-03-03 | Bellweather Farms | Chemical induction of lactation |
WO2011038228A1 (en) | 2009-09-24 | 2011-03-31 | President And Fellows Of Harvard College | Bent nanowires and related probing of species |
US9328335B2 (en) | 2009-12-30 | 2016-05-03 | Board Of Trustees Of Michigan State University | Method to produce acetyldiacylglycerols (ac-TAGs) by expression of an acetyltransferase gene isolated from Euonymus alatus (burning bush) |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
US8574832B2 (en) * | 2010-02-03 | 2013-11-05 | Massachusetts Institute Of Technology | Methods for preparing sequencing libraries |
US20110237461A1 (en) * | 2010-03-17 | 2011-09-29 | The Regents Of The University Of Michigan | Using phage epitopes to profile the immune response |
MX347515B (es) | 2010-04-01 | 2017-04-28 | Oncomed Pharmaceuticals Inc * | Agentes que se unen al receptor encrespado y usos de los mismos. |
GB2491795A (en) | 2010-04-06 | 2012-12-12 | Massachusetts Inst Technology | Gene-expression profiling with reduced numbers of transcript measurements |
US9125931B2 (en) | 2010-04-06 | 2015-09-08 | Massachusetts Institute Of Technology | Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers |
CN106771219B (zh) * | 2010-06-17 | 2020-04-07 | 皇家飞利浦电子股份有限公司 | 多表位测定 |
EP2407242A1 (en) | 2010-07-13 | 2012-01-18 | Dublin City University | Direct clone analysis and selection technology |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
WO2013119923A1 (en) | 2012-02-09 | 2013-08-15 | The Regents Of The University Of Michigan | Different states of cancer stem cells |
MY193914A (en) | 2012-03-05 | 2022-11-01 | Oy Arctic Partners Ab | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume |
WO2014005076A2 (en) | 2012-06-29 | 2014-01-03 | The Regents Of The University Of Michigan | Methods and biomarkers for detection of kidney disorders |
CN104768579A (zh) | 2012-10-23 | 2015-07-08 | 昂科梅德制药有限公司 | 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法 |
WO2014105910A1 (en) | 2012-12-26 | 2014-07-03 | Oncosynergy, Inc. | ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF |
JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路インヒビターによる処置の方法およびモニタリング |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
US9907833B2 (en) | 2013-07-25 | 2018-03-06 | University Of Florida Research Foundation, Incorporated | Use of relaxin to treat placental syndromes |
US10392629B2 (en) | 2014-01-17 | 2019-08-27 | Board Of Trustees Of Michigan State University | Increased caloric and nutritional content of plant biomass |
US10234465B2 (en) | 2014-03-19 | 2019-03-19 | The University Of North Carolina At Chapel Hill | BCL6 expression in eutopic endometrium as a marker for endometriosis and subfertility |
PE20170298A1 (es) | 2014-03-28 | 2017-04-18 | Opko Diagnostics Llc | Composiciones y metodos relacionados con el diagnostico del cancer de prostata |
US10670611B2 (en) | 2014-09-26 | 2020-06-02 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
PT3253800T (pt) | 2015-03-27 | 2021-04-28 | Opko Diagnostics Llc | Padrões de antigénio da próstata e suas utilizações |
US11474105B2 (en) | 2016-03-31 | 2022-10-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for SIRT1 expression as a marker for endometriosis and subfertility |
CA3041717A1 (en) | 2016-11-09 | 2018-05-17 | North Carolina State University | Treatment of allergic diseases with chimeric protein |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7602422A (nl) * | 1976-03-08 | 1977-09-12 | Leuven Res & Dev Vzw | Trombosetest. |
US4849353A (en) * | 1980-09-30 | 1989-07-18 | Cornell Research Foundation, Inc. | Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof |
US4689323A (en) * | 1983-09-26 | 1987-08-25 | Miles Laboratories, Inc. | Covalently bound heparin--antithrombin-III complex |
US5026653A (en) * | 1985-04-02 | 1991-06-25 | Leeco Diagnostic, Inc. | Scavenger antibody mixture and its use for immunometric assay |
US4737456A (en) * | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
SE8601645D0 (sv) * | 1986-04-11 | 1986-04-11 | Ulf R Nilsson | Immunologiskt forfarande |
US5114863A (en) * | 1986-09-30 | 1992-05-19 | Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College | Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody |
US5223441A (en) * | 1986-10-09 | 1993-06-29 | Syntex (U.S.A.) Inc. | Receptors for immune complexes |
US5187067A (en) * | 1986-12-15 | 1993-02-16 | Teijin Limited | Immunological determination of free human protein S and C4bp-protein S complex |
EP0288793A3 (en) * | 1987-04-22 | 1990-04-25 | Abbott Laboratories | Cartridge and methods for performing a solid-phase immunoassay |
DE3727238A1 (de) * | 1987-08-14 | 1989-02-23 | Henning Berlin Gmbh | Immunologisches bestimmungsverfahren zur bestimmung von hapteneigenschaften aufweisenden freien substanzen |
SE9002480D0 (sv) * | 1990-07-23 | 1990-07-23 | Hans Lilja | Assay of free and complexed prostate-specific antigen |
US5324634A (en) * | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
-
1993
- 1993-12-29 US US08/174,964 patent/US5599677A/en not_active Expired - Lifetime
-
1994
- 1994-12-22 DE DE69434286T patent/DE69434286T2/de not_active Expired - Lifetime
- 1994-12-22 EP EP95906713A patent/EP0741868B1/en not_active Expired - Lifetime
- 1994-12-22 ES ES95906713T patent/ES2238678T3/es not_active Expired - Lifetime
- 1994-12-22 AU AU15187/95A patent/AU1518795A/en not_active Abandoned
- 1994-12-22 JP JP51816495A patent/JP3486413B2/ja not_active Expired - Lifetime
- 1994-12-22 AT AT95906713T patent/ATE290212T1/de active
- 1994-12-22 WO PCT/US1994/014902 patent/WO1995018381A1/en active IP Right Grant
-
1995
- 1995-05-23 US US08/447,576 patent/US5672480A/en not_active Expired - Lifetime
-
2003
- 2003-08-05 JP JP2003286450A patent/JP3833637B2/ja not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016194437A (ja) * | 2015-03-31 | 2016-11-17 | 株式会社Lsiメディエンス | 前立腺特異抗原の測定方法及び測定キット |
Also Published As
Publication number | Publication date |
---|---|
US5672480A (en) | 1997-09-30 |
JP3833637B2 (ja) | 2006-10-18 |
ATE290212T1 (de) | 2005-03-15 |
EP0741868B1 (en) | 2005-03-02 |
DE69434286D1 (de) | 2005-04-07 |
US5599677A (en) | 1997-02-04 |
JP3486413B2 (ja) | 2004-01-13 |
ES2238678T3 (es) | 2005-09-01 |
JPH09508969A (ja) | 1997-09-09 |
AU1518795A (en) | 1995-07-17 |
EP0741868A1 (en) | 1996-11-13 |
WO1995018381A1 (en) | 1995-07-06 |
DE69434286T2 (de) | 2005-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3833637B2 (ja) | 前立腺特異抗原の免疫検定法 | |
US5912158A (en) | Prostate specific antigen (PSA)-proteinase inhibitor complexes | |
JP4274330B2 (ja) | cPSAの測定方法 | |
US4731326A (en) | Disease diagnosis by detection of shed normal tissue antigens | |
US5840501A (en) | Determination of cPSA | |
Oh et al. | Point-of-care fluorescence immunoassay for prostate specific antigen | |
JP4755112B2 (ja) | 抗原を測定するための試薬及び抗原の測定方法 | |
US6379550B1 (en) | Method for detecting PSA and its molecular forms using thiophilic gel | |
US6692643B2 (en) | Method for detecting PSA and its molecular forms using thiophilic gel on magnetic beads | |
JP2009522581A (ja) | 競合免疫アッセイによるfk778の濃度の決定 | |
JP2000515854A (ja) | 脳タンパク質s―100の存在の測定方法 | |
CA2178504C (en) | Immunoassays for prostate specific antigen | |
US6548260B1 (en) | Detection of PSA-α2-macroglobulin complex in a biological fluid | |
JP3709078B2 (ja) | ジアセチルポリアミンの測定法及びキット | |
JP2878317B2 (ja) | ラミニン測定試薬 | |
CA2546529A1 (en) | Immunoassays for prostate specific antigen | |
JP4451784B2 (ja) | 前立腺癌腫瘍マーカー | |
JPH09234068A (ja) | モノクローナル/ポリクローナルサンドイッチイムノアッセイにおいて遊離および複合被分析物と等モル応答するモノクローナル抗体の製造方法 | |
JP2000266747A (ja) | 抗ラットIgE抗体を用いたラットIgEの測定キット及び測定方法 | |
PL188200B1 (pl) | Oznaczanie cPSA | |
JPH0843398A (ja) | 癌の診断方法 | |
JPH02114181A (ja) | ヒトプラスミン−α↓2−プラスミンインヒビター複合体測定用の免疫学的測定試薬 | |
IL130230A (en) | Method for the detection of prostate cancer from blood levels of prostate specific antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050118 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050411 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050713 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050927 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060324 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060627 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060719 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100728 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110728 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120728 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130728 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |